Considering B3GnT2 has recently been reported to modify several ligands and receptors that alter T-cell activation via interaction with cancer cells [41], there may be a more general role for B3GnT2 in the regulation of cancer-relevant signalling events, such as Wnt/β-catenin signalling. The gene discussed is B3GNT2; the disease is cancer.